Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Karim Fizazi, MD, PhD, of the University of Paris-Sud, Orsay, France, presents the objectives and motivations behind the CheckMate 9KD trial (NCT03338790). This trial investigated nivolumab in combination with either rucaparib, docetaxel or enzalutamide in men with castration-resistant metastatic prostate cancer. Prof. Fizazi highlights how this trial was created to help find novel drug combinations that could be given to different patients.
CheckMate 9KD: finding novel drug combinations for patients in all stages of treatment
